One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood.v128.22.104.104
Copy DOI Journal: Blood |  Publication Date: Dec 2, 2016 |
 Citations: 11 |
Affiliation: City Of Hope National Medical Center, Willamette Valley Cancer Institute and Research Center, Oncology Specialists, Charles University, Loyola University Medical Center, Arizona Oncology, Advocate Lutheran General Hospital, Seagen (United States), Huntsman Cancer Institute, University of Utah, Virginia Commonwealth University Medical Center, Oncology Hematology Care, Comprehensive Cancer Centers of Nevada, University Hospital and Clinics, Summit Medical Group (United States), Texas Oncology, The University of Texas MD Anderson Cancer Center, Mayo Clinic, Johns Hopkins University, Johns Hopkins Bayview Medical Center, Baylor University Medical Center, Virginia Cancer Specialists, Rocky Mountain Cancer Centers, Washington University in St. LouisResults of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
